TABLE 8.

Differences in the ranking of future research priorities for idiopathic epilepsy (IE) in dogs among neurologists (n = 101), general practice (GP) vets (n = 152), and owners (n = 575). Research areas were ranked from 1 (top priority) to 18 (lowest priority) and data from 2016 and 2020 are pooled

Research area	Owners (n = 575)	Neurologists (n = 101)	GP Vets (n = 152)	Kruskall‐Wallis
	Median [IQR]	Median [IQR]	Median [IQR]	F	P
Existing AEDs	4.0 [2.0‐9.0]	4.0 [2.0‐7.0]	4.0 [2.0‐8.0]	5.97	.05
New AEDs	4.0 [2.0‐10.0]	4.0 [1.0‐7.0]	5.0 [3.0‐8.0]	7.89	.02
Vet education	7.0 [4.0‐12.0]	9.0 [5.0‐13.5]	9.0 [5.0‐12.0]	11.21	.01
Adverse effects of AEDs	6.0 [4.0‐11.0]	8.0 [6.0‐11.0]	6.0 [4.0‐10.0]	8.83	.01
Genetic etiology	7.0 [3.0‐12.0]	4.0 [3.0‐10.0]	7.0 [3.0‐11.0]	8.85	.01
Nongenetic etiology	9.0 [5.0‐13.0]	8.0 [4.0‐12.0]	7.0 [4.0‐11.0]	7.52	.02
Non‐AED management	6.0 [3.0‐12.0]	7.0 [4.0‐7.0]	7.0 [3.0‐11.0]	0.01	.99
Seizure detection	8.0 [4.0‐13.0]	7.0 [3.0‐11.0]	9.0 [5.0‐14.0]	9.61	.01
Diagnosing epilepsy	9.0 [5.0‐12.0]	7.0 [4.0‐10.5]	5.0 [2.0‐9.0]	38.45	<.001
Lifespan	10.0 [7.0‐14.0]	11.0 [8.0‐14.0]	11.0 [7.0‐14.0]	1.46	.48
Seizure classification	10.0 [6.0‐14.0]	7.0 [3.0‐10.0]	7.0 [4.0‐11.0]	50.78	<.001
Prognosis	11.0 [7.0‐14.0]	10.0 [7.0‐13.0]	9.0 [6.0‐12.0]	8.40	.02
Comorbidities	11.0 [7.0‐14.0]	11.0 [6.5‐14.0]	10.0 [7.0‐13.0]	2.76	.25
Anxiety	12.0 [7.0‐15.0]	13.0 [10.0‐15.0]	13.5 [10.0‐16.0]	18.02	<.001
Hyperactivity	14.0 [10.0‐16.0]	14.0 [12.0‐17.0]	15.0 [13.0‐17.0]	21.83	<.001
Physical capabilities	12.0 [8.0‐15.0]	15.0 [11.0‐17.0]	14.0 [11.0‐16.0]	47.95	<.001
Attention	13.0 [9.0‐16.0]	14.0 [11.5‐16.0]	15.0 [11.25‐16.0]	15.20	<.001
Social interactions	14.0 [9.0‐17.0]	15.0 [13.0‐17.0]	15.0 [12.0‐17.0]	15.15	<.001

Abbreviations: AED, antiepileptic drug; IQR, interquartile range; MW, Mann‐Whitney U test result.